Loading...
Loading...
KALA| Name | Value |
|---|---|
| Revenues | 1,228.0K |
| Cost of Revenue | 2,560.0K |
| Gross Profit | -1,332.0K |
| Operating Expense | 9,154.0K |
| Operating I/L | -10,251.0K |
| Other Income/Expense | -2,592.0K |
| Interest Income | 354.0K |
| Pretax | -12,843.0K |
| Income Tax Expense | 1,017.0K |
| Net Income/Loss | -13,860.0K |
Kala Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing and commercializing therapies for eye diseases. The company's product candidates include KPI-012 for corneal epithelial defects, EYSUVIS for dry eye disease, and INVELTYS for post-operative inflammation. Additionally, Kala Pharmaceuticals is working on preclinical products such as KPI-287 for retinal diseases and a selective glucocorticoid receptor modulators program. These products are designed to address unmet medical needs in the ophthalmology market, providing potential revenue streams through the successful development and commercialization of innovative eye disease treatments.
